Table 1.
Demographic, clinical, and blood test characteristics of the global population and after sorting for treatment response.
| Global Cohort (n = 62) |
Responders (n = 47) |
Non-Responders (n = 15) |
p-Value | |
|---|---|---|---|---|
| Age, years | 68.5 (62.0–74.0) | 66.0 (61.3–72.8) | 71.0 (64.8–75.0) | 0.17 |
| Gender (M/F) | 45/17 | 34/13 | 11/4 | 0.94 |
| Smoking status, n (no/former/yes) | 3/45/11 | 3/33/9 | 0/12/2 | 0.51 |
| Histological type, n (ADK/SQ) | 53/9 | 41/6 | 12/3 | 0.49 |
| PD-L1, n (1–49%/<1%) | 30/30 | 23/22 | 7/8 | 0.77 |
| Stage T, n (T1/T2/T3/T4) | 4/2/3/53 | 4/2/2/39 | 0/0/1/14 | 0.53 |
| Stage N, n (N0/N1/N2/N3) | 3/9/11/38 | 3/9/8/26 | 0/0/3/12 | 0.18 |
| Deceased, n (yes/no) | 23/37 | 10/35 | 13/2 | <0.0001 |
| Overall survival, (months) | 12.1 (7.4–24.3) | 14.5 (9.1–31.9) | 7.5 (4.2–11.2) | 0.0015 |
| Hb (g/dL) | 12.3 ± 1.7 | 12.6 ± 1.7 | 11.9 ± 1.8 | 0.47 |
| RDW, (%) | 14.7 (13.8–15.8) | 14.7 (13.4–15.8) | 14.8 (14.1–15.6) | 0.53 |
| WBC, n (×109 L) | 8.86 (7.40–11.15) | 8.74 (6.91–10.72) | 8.96 (7.96–13.73) | 0.29 |
| Neutrophils, n (×109 L) | 6.00 (4.10–7.60) | 5.62 (3.80–7.37) | 6.40 (5.59–11.95) | 0.074 |
| Lymphocytes, n (×109 L) | 1.70 (1.30–2.20) | 1.80 (1.40–2.44) | 1.40 (1.10–1.98) | 0.10 |
| Monocytes, n (×109 L) | 0.60 (0.50–0.80) | 0.60 (0.50–0.80) | 0.60 (0.50–0.80) | 0.55 |
| Platelets, n (×109 L) | 287 (253–355) | 287 (254–362) | 293 (247–349) | 0.91 |
| NLR | 3.45 (2.18–5.47) | 3.31 (2.15–4.12) | 5.36 (2.78–10.82) | 0.019 |
| NMR | 9.75 (7.60–11.80) | 9.20 (7.45–11.20) | 14.00 (8.82–21.20) | 0.013 |
| MLR | 0.33 (0.23–0.53) | 0.33 (0.23–0.51) | 0.40 (0.21–0.55) | 0.67 |
| PLR | 169 (118–246) | 163 (114–244)) | 209 (131–248) | 0.17 |
| SII | 985 (624–1838) | 945 (552–1373) | 1395 (929–3334) | 0.025 |
| AISI | 543 (277–1072) | 487 (273–955) | 837 (357–1524) | 0.20 |
ADK: adenocarcinoma; AISI: aggregate index of systemic inflammation; F: female; Hb: hemoglobin; M: male; MLR: monocyte to lymphocyte ratio; NLR: neutrophil to lymphocyte ratio; NMR: neutrophil to monocyte ratio; PD-L1: programmed death ligand 1; RDW: red cell distribution width; SII: systemic inflammation index; SQ: squamous cell cancer; WBC: white blood cells.